Yıldız, AbdulkerimMaral, SenemAlbayrak, MuratPala, ÇiğdemCömert, PınarAfacan Öztürk, Hacer BernaŞahin, Osman2024-12-282024-12-2820201309-38781309-3878https://doi.org/10.18521/ktd.549666https://dergipark.org.tr/tr/download/article-file/990065https://dergipark.org.tr/tr/pub/ktd/issue/52800/549666https://hdl.handle.net/20.500.12684/17857Objective: Theaim of this study was to investigate the survival data of patients with acutemyeloid leukemia (AML) and to determine the risk factors that can be easily evaluated.Method: Aretrospective analysis  was made of the AML patients admitted to our center between2009-2018. Demographic data and disease data were analyzed and response rates,overall survival (OS) and progression-free survival (PFS) rates werecalculated. Factors affecting survival were determined using Cox-regressionanalysis.Results: Atotal of 119 patients were included in the study during the 9-year studyperiod. Of these, 21 patients had secondary AML and 11 had acute promyelocyticleukemia (APL). The mean follow-up period was 12.43 ± 15.63 months. OS of allpatients was 9.20 months and PFS was 7.23 months. Age and leukocyte count atthe time of diagnosis were found to have a significant impact on both OS andPFS (p lt;0.05).Conclusion:In addition to genetic and molecular features, which are expensive and noteasily available, the age and leukocyte count of AML patients remain important asprognostic factors.en10.18521/ktd.549666info:eu-repo/semantics/openAccessleukemiasurvivalageHealth Care AdministrationArticle121511DergiPark: 549666